Avalyn Pharma Inc. (AVLN) stock
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.69−0.23 (-0.82%)
Close on Nov 18, 2026Market cap $1.23BP/E –Yield –
Avalyn Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.72M | – |
See a number that looks wrong?